Article Text

PDF
Continuation of anakinra despite the development of a pruritic rash in an otherwise refractory case of adult-onset Still’s disease
  1. S Vordenbäumen,
  2. B Ostendorf,
  3. O Sander,
  4. J Richter,
  5. M Schneider
  1. Department of Endocrinology, Diabetology and Rheumatology, University Hospital Düsseldorf, Düsseldorf, Germany
  1. Dr S Vordenbäumen, Section of Rheumatology, Department of Endocrinology, Diabetology and Rheumatology, University Hospital Düsseldorf, Moorenstrasse 5, 40225 Düsseldorf, Germany; Stefan.Vordenbaeumen{at}med.uni-duesseldorf.de

Statistics from Altmetric.com

The human recombinant IL-1 receptor antagonist anakinra is used in rheumatoid arthritis,1 systemic lupus erythematosus2 and adult-onset Still’s disease (AOSD).35 Various side effects of mild to moderate severity including injection-site reactions,1 4 erythema and pruritus are known.1

We report the case of a 57-year-old male patient with Italian ancestry and chronic, long-standing AOSD. The patient presented himself in 1997 with daily high-spiking fevers up to 40°C, a faint rash, arthralgias, myalgias and splenomegaly of 15 cm. Ferritin was 2733 μg/l, C-reactive protein (CRP) was 12,4 mg/dl, white blood cell count was 42 000/μl. Antinuclear antibodies and antineutrophil cytoplasmic antibodies …

View Full Text

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.